Omeros (FRA:3O8) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Omeros FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Omeros's Free Cash Flow for the three months ended in Dec. 2023 was €-31.94 Mil. Omeros's Revenue for the three months ended in Dec. 2023 was €0.00 Mil. Therefore, Omeros's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Omeros's current FCF Yield % is 30.77%.

The historical rank and industry rank for Omeros's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Omeros was -56.42%. The lowest was -10774.03%. And the median was -349.22%.

FRA:3O8's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -145.04
* Ranked among companies with meaningful FCF Margin % only.

Omeros FCF Margin % Historical Data

The historical data trend for Omeros's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros FCF Margin % Chart

Omeros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Omeros Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Omeros's FCF Margin %

For the Biotechnology subindustry, Omeros's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omeros's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Omeros's FCF Margin % falls into.

Omeros FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Omeros's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	68.133	/	0
	=	%

Omeros's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-31.935	/	0
	=	%

Omeros FCF Margin % Related Terms

Thank you for viewing the detailed overview of Omeros's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros (FRA:3O8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

OMER:USA 3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros (FRA:3O8) Headlines

No Headlines